A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- Registration Number
- NCT00002187
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Brief Summary
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
- Detailed Description
This is a multicenter, prospective, randomized, open-label study comparing 2 dosage schedules of ISIS 2922.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (17)
Retina - Vitreous Associates Med Group
🇺🇸Los Angeles, California, United States
Novum Inc
🇺🇸Seattle, Washington, United States
Dr Julio Perez
🇺🇸Fort Lauderdale, Florida, United States
Univ of Illinois
🇺🇸Chicago, Illinois, United States
Hahnemann Univ Hosp
🇺🇸Philadelphia, Pennsylvania, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States
Vitreo - Retinal Consultants
🇺🇸New York, New York, United States
New York Univ Med Ctr
🇺🇸New York, New York, United States
Indiana Univ Med Ctr
🇺🇸Indianapolis, Indiana, United States
Duke Univ
🇺🇸Durham, North Carolina, United States
Univ of California San Francisco / SF Gen Hosp
🇺🇸San Francisco, California, United States
Dr Jacob Lalezari
🇺🇸San Francisco, California, United States
Community Eye Med Group
🇺🇸Pasadena, California, United States
Charlotte Eye Ear Nose & Throat Association
🇺🇸Charlotte, North Carolina, United States
Georgia Retina
🇺🇸Atlanta, Georgia, United States
Chicago Ctr for Clinical Research
🇺🇸Chicago, Illinois, United States
Dr Alan Palestine
🇺🇸Washington, District of Columbia, United States